Remdesivir and related
Remdesivir is a prodrug form of the antiviral nucleotide analog GS-443902.Upon entry into cells,
remdesivir is metabolized into the intermediate metabolite GS-441524, which is then further
metabolized to the active nucleotide triphosphate GS-443902 that induces RNA chain termination
and
inhibits viral polymerases.Remdesivir reduces viral titers in primary human airway epithelial
(HAE)
cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute
respiratory syndrome CoV (SARS-CoV; EC50s = 0.074 and 0.069 µM, respectively). It reduces
infectious
virus production in SARS-CoV-2-infected HAE cells (EC50 = 10 nM).
In vivo, remdesivir (25 and 50 mg/kg) reduces lung viral titers and prevents weight loss in a
mouse
model of SARS-CoV infection.Remdesivir (25 mg/kg) also reduces lung viral titers and lung
hemorrhage
and improves pulmonary function in mice infected with a chimeric SARS-CoV encoding the
SARS-CoV-2
RNA-dependent RNA polymerase (RdRp).Formulations containing remdesivir have been used in the
treatment of COVID-19.